Calendar An icon of a desk calendar. Cancel An icon of a circle with a diagonal line across. Caret An icon of a block arrow pointing to the right. Email An icon of a paper envelope. Facebook An icon of the Facebook "f" mark. Google An icon of the Google "G" mark. Linked In An icon of the Linked In "in" mark. Logout An icon representing logout. Profile An icon that resembles human head and shoulders. Telephone An icon of a traditional telephone receiver. Tick An icon of a tick mark. Is Public An icon of a human eye and eyelashes. Is Not Public An icon of a human eye and eyelashes with a diagonal line through it. Pause Icon A two-lined pause icon for stopping interactions. Quote Mark A opening quote mark. Quote Mark A closing quote mark. Arrow An icon of an arrow. Folder An icon of a paper folder. Breaking An icon of an exclamation mark on a circular background. Camera An icon of a digital camera. Caret An icon of a caret arrow. Clock An icon of a clock face. Close An icon of the an X shape. Close Icon An icon used to represent where to interact to collapse or dismiss a component Comment An icon of a speech bubble. Comments An icon of a speech bubble, denoting user comments. Ellipsis An icon of 3 horizontal dots. Envelope An icon of a paper envelope. Facebook An icon of a facebook f logo. Camera An icon of a digital camera. Home An icon of a house. Instagram An icon of the Instagram logo. LinkedIn An icon of the LinkedIn logo. Magnifying Glass An icon of a magnifying glass. Search Icon A magnifying glass icon that is used to represent the function of searching. Menu An icon of 3 horizontal lines. Hamburger Menu Icon An icon used to represent a collapsed menu. Next An icon of an arrow pointing to the right. Notice An explanation mark centred inside a circle. Previous An icon of an arrow pointing to the left. Rating An icon of a star. Tag An icon of a tag. Twitter An icon of the Twitter logo. Video Camera An icon of a video camera shape. Speech Bubble Icon A icon displaying a speech bubble WhatsApp An icon of the WhatsApp logo. Information An icon of an information logo. Plus A mathematical 'plus' symbol. Duration An icon indicating Time. Success Tick An icon of a green tick. Success Tick Timeout An icon of a greyed out success tick. Loading Spinner An icon of a loading spinner.

Dundee University spin-out firm forms German partnership for drug discovery deal

Professor Andrew Hopkins, second left, and ex scientia team members.
Professor Andrew Hopkins, second left, and ex scientia team members.

A Dundee University spin-out company has formed a partnership with a German group aimed at developing a drug which can treat cancer and other diseases more effectively.

Ex scientia and Evotec AG will work together to discover bispecific small molecule immuno-oncology therapeutics.

The Dundee biotech company has expertise in developing more effective medicines for a wide range of diseases.

Evotec is a drug discovery alliance and development company focused on producing high quality stand-alone and integrated drug discovery solutions.

It operates worldwide with pharmaceutical and biotechnology companies, academics, patient advocacy groups and venture capitalists.

Ex scientia will contribute its unique algorithmic design platform while Evotec, mainly through its Toulouse site, will be responsible for medicinal chemistry, in vitro and in vivo pharmacology as well as development capabilities and expertise.

Application of bispecific small molecules is seen as an exciting strategy to significantly expand and enhance drug treatment beyond conventional single target therapies.

The initial focus will be cancer-related adenosine targets which are increasingly recognised to play important roles in immuno-oncology.

Combining the specialisms of the partners is thought to hold great promise in boosting the effect and addressing larger patient populations through a single small molecule drug.

Professor Andrew Hopkins, chief executive of ex Scientia, said“This is an ideal partnership to develop an innovative immuno-oncology portfolio where our focus is on delivering efficacious drug candidates to tackle the inherent challenges of the complex biology.

“Evotec have an excellent track record in project delivery and their proven track record in regarding efficiency gains in drug discovery chime with our own.”

Dr Cord Dohrmann, chief scientific Officer of Evotec, commented: “Polypharmacy is a widely used strategy to manage diseases more effectively.

“Ex scientia has built an outstanding platform to purposely design bispecific small molecules that can address multiple targets through a single molecule.

“Together we are well positioned to discover and develop a new generation of small molecule immuno-oncology therapies.”

Already a subscriber? Sign in